224 related articles for article (PubMed ID: 34491804)
1. Echinocandins Accelerate Particle Transport Velocity in the Murine Tracheal Epithelium: Dependency on Intracellular Ca
Müller S; Droll MC; Koch C; Weiterer S; Weigand MA; Sander M; Henrich M
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0066921. PubMed ID: 34491804
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.
Fleischhacker M; Radecke C; Schulz B; Ruhnke M
Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):127-31. PubMed ID: 18057972
[TBL] [Abstract][Full Text] [Related]
5. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
6. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
10. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
11. A 20:1 synergetic mixture of cafedrine/theodrenaline accelerates particle transport velocity in murine tracheal epithelium via IP
Schmidt G; Rienas G; Müller S; Edinger F; Sander M; Koch C; Henrich M
Front Pharmacol; 2023; 14():1155930. PubMed ID: 37654612
[No Abstract] [Full Text] [Related]
12. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
Lockhart SR; Zimbeck AJ; Baddley JW; Marr KA; Andes DR; Walsh TJ; Kauffman CA; Kontoyiannis DP; Ito JI; Pappas PG; Chiller T
Antimicrob Agents Chemother; 2011 Aug; 55(8):3944-6. PubMed ID: 21670187
[TBL] [Abstract][Full Text] [Related]
13. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
14. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2008 Jan; 52(1):321-8. PubMed ID: 17938191
[TBL] [Abstract][Full Text] [Related]
16. Caspofungin induces the release of Ca
Müller S; Koch C; Weiterer S; Weigand MA; Sander M; Henrich M
Sci Rep; 2020 Jul; 10(1):11723. PubMed ID: 32678179
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskov A; Ramani R
J Clin Microbiol; 2008 Jul; 46(7):2155-9. PubMed ID: 18463213
[TBL] [Abstract][Full Text] [Related]
18. Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.
Dimopoulou D; Hamilos G; Tzardi M; Lewis RE; Samonis G; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(1):229-36. PubMed ID: 24145540
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]